Hôpitaux du Leman
Welcome,         Profile    Billing    Logout  
 3 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BEDJAOUI, Ahmed
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
BACHA, Khoutir MAHOUR
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting
3
348
Europe
Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI
Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms
09/25
09/27

Download Options